Literature DB >> 22057236

Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.

M Fernanda Amary1, Stephen Damato, Dina Halai, Malihe Eskandarpour, Fitim Berisha, Fiona Bonar, Stan McCarthy, Valeria R Fantin, Kimberly S Straley, Samira Lobo, Will Aston, Claire L Green, Rosemary E Gale, Roberto Tirabosco, Andrew Futreal, Peter Campbell, Nadège Presneau, Adrienne M Flanagan.   

Abstract

Ollier disease and Maffucci syndrome are characterized by multiple central cartilaginous tumors that are accompanied by soft tissue hemangiomas in Maffucci syndrome. We show that in 37 of 40 individuals with these syndromes, at least one tumor has a mutation in isocitrate dehydrogenase 1 (IDH1) or in IDH2, 65% of which result in a R132C substitution in the protein. In 18 of 19 individuals with more than one tumor analyzed, all tumors from a given individual shared the same IDH1 mutation affecting Arg132. In 2 of 12 subjects, a low level of mutated DNA was identified in non-neoplastic tissue. The levels of the metabolite 2HG were measured in a series of central cartilaginous and vascular tumors, including samples from syndromic and nonsyndromic subjects, and these levels correlated strongly with the presence of IDH1 mutations. The findings are compatible with a model in which IDH1 or IDH2 mutations represent early post-zygotic occurrences in individuals with these syndromes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057236     DOI: 10.1038/ng.994

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   41.307


  11 in total

1.  Cartilaginous lesions of bone.

Authors:  K K Unni
Journal:  J Orthop Sci       Date:  2001       Impact factor: 1.601

2.  Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.

Authors:  Matthias Preusser; Adelheid Wöhrer; Susanne Stary; Romana Höftberger; Berthold Streubel; Johannes A Hainfellner
Journal:  J Neuropathol Exp Neurol       Date:  2011-08       Impact factor: 3.685

3.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

Review 4.  IDH mutations in glioma and acute myeloid leukemia.

Authors:  Lenny Dang; Shengfang Jin; Shinsan M Su
Journal:  Trends Mol Med       Date:  2010-08-05       Impact factor: 11.951

Review 5.  Enchondromatosis: insights on the different subtypes.

Authors:  Twinkal C Pansuriya; Herman M Kroon; Judith V M G Bovée
Journal:  Int J Clin Exp Pathol       Date:  2010-06-26

6.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

7.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

8.  Genome-wide analysis of Ollier disease: Is it all in the genes?

Authors:  Twinkal C Pansuriya; Jan Oosting; Tibor Krenács; Antonie H M Taminiau; Suzan H M Verdegaal; Luca Sangiorgi; Raf Sciot; Pancras C W Hogendoorn; Karoly Szuhai; Judith V M G Bovée
Journal:  Orphanet J Rare Dis       Date:  2011-01-14       Impact factor: 4.123

9.  Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.

Authors:  Daniel Krell; Mawuelikem Assoku; Malcolm Galloway; Paul Mulholland; Ian Tomlinson; Chiara Bardella
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.752

10.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.

Authors:  M Fernanda Amary; Krisztian Bacsi; Francesca Maggiani; Stephen Damato; Dina Halai; Fitim Berisha; Robin Pollock; Paul O'Donnell; Anita Grigoriadis; Tim Diss; Malihe Eskandarpour; Nadège Presneau; Pancras Cw Hogendoorn; Andrew Futreal; Roberto Tirabosco; Adrienne M Flanagan
Journal:  J Pathol       Date:  2011-05-19       Impact factor: 9.883

View more
  131 in total

1.  Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.

Authors:  Zachary J Reitman; Sergey A Sinenko; Eric P Spana; Hai Yan
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Genetics: IDH mosaicism in enchondromatosis syndromes.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

3.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

Review 4.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

5.  Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.

Authors:  Shuyu Hao; Christopher S Hong; Jie Feng; Chunzhang Yang; Prashant Chittiboina; Junting Zhang; Zhengping Zhuang
Journal:  J Neurosurg       Date:  2015-10-16       Impact factor: 5.115

Review 6.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

7.  Reply to: Familial syndromes associated with intracranial tumours: a review.

Authors:  Fonnet E Bleeker
Journal:  Childs Nerv Syst       Date:  2015-08-09       Impact factor: 1.475

8.  D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.

Authors:  Tie Li; Christopher D Cox; Byram H Ozer; Nhung T Nguyen; HuyTram N Nguyen; Thomas J Lai; Sichen Li; Fei Liu; Harley I Kornblum; Linda M Liau; Phioanh L Nghiemphu; Timothy F Cloughesy; Albert Lai
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

Review 9.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09

10.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.